OPTUNE® TREATMENT FOR
GLIOBLASTOMA (GBM)
Intended for US healthcare professionals only.

In recurrent GBM,
Patients treated with Optune had improved cognitive and emotional functioning when compared with patients treated with chemotherapy alone*


Quality of life for patients treated with Optune® for glioblastoma (GBM): cognitive and emotional functioning

*Therapy options were the physician's best choice for chemotherapy. The best available therapy was prescribed according to local practice and depending on prior treatment exposure.
  • No clinically meaningful differences were found in global health and social functioning

  • Data collected by EORTC QLQ-C30 questionnaire


Fewer treatment-related adverse events occurred in patients treated with Optune

Quality of life for patients treated with Optune®: common cancer treatment-related adverse symptoms

  • For a complete list of adverse events, please refer to the Optune Instructions for Use

*Therapy options were the physician's best choice for chemotherapy. The best available therapy was prescribed according to local practice and depending on prior treatment exposure.
  • Optune monotherapy was associated with more favorable changes in patient-reported symptoms

  • Data collected per EORTC QLQ-C30 questionnaire

EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer core quality of life questionnaire; GBM, glioblastoma.

Reference: 1. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).